Search clinical trials for: BNT153

Total 30 results

BioNTech SE

Recruiting

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Solid Tumor

United States, Czechia
BioNTech SE

Active, not recruiting

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Solid Tumor

United States, Spain
University of Southampton
BioNTech SE

Completed

HARE-40: HPV Anti-CD40 RNA vaccinE (HARE-40)

Unknown Primary Tumors | Head and Neck Neoplasm | Cervical Neoplasm | Penile Neoplasms Malignant | Human Papilloma Virus Related Carcinoma

United Kingdom
Blue Note Therapeutics
Healthcare Innovation Technology Lab

Completed

Blue Note Therapeutics Product BNT 103 Usability and User Engagement

Breast Cancer Female

United States
BioNTech SE

Recruiting

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Solid Tumor

United States, Spain, Singapore, United Kingdom
BioNTech SE

Recruiting

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Genital Herpes Simplex Type 2

United States
Chulalongkorn University
BioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaborators

Recruiting

Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditions

Thailand
BioNTech SE

Recruiting

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
DualityBio Inc.
BioNTech SE

Recruiting

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

HER2-positive Breast Cancer

China
BioNTech SE
Regeneron Pharmaceuticals

Active, not recruiting

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, Italy, Australia, United Kingdom, Poland
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ≥ 50%

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
BioNTech SE

Terminated

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT)

Prostate Cancer

United States, Germany, United Kingdom, Hungary
Bristol-Myers Squibb

No longer available

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Multiple Myeloma
Technovalia, Pty Ltd
Chulalongkorn University; Southern Star Research Pty Ltd.; BioNet-Asia

Active, not recruiting

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

COVID-19, SARS CoV 2 Infection

Australia
BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
Seoul National University Hospital

Completed

Milrinone During Living Donor Hepatectomy

Hepatectomy

Korea, Republic of
BioNTech SE

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

Non-Small Cell Lung Cancer

Spain, Germany, Turkey, United States, Hungary, United Kingdom, Poland
Methodist Health System

Enrolling by invitation

Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction

Heart Failure

United States
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, Australia
BioNTech SE
DualityBio Inc.

Not yet recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
Bioprojet

Completed

Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users

Healthy | Drug Abuse

Canada
The Cleveland Clinic

Completed

Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity

Obesity

United States
Center for Weight Management, California
American Society of Bariatric Physicians

Completed

Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal (PC-II)

Obesity | Phentermine Withdrawal

United States
VIVUS LLC
Covance; Sentrx

Completed

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Stanford University

Completed

FDA Approved Medication to Reduce Binge Eating and/or Purging

Bulimia Nervosa | Binge Eating Disorder

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Cardiovascular System in Obesity: Effect of Treatment

Heart Diseases | Vascular Diseases | Obesity
Federico II University

Completed

Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics

Infantile Colics
Gangnam Severance Hospital

Completed

Orlistat/Phentermine Versus Placebo/Phentermine

Obesity | Overweight

Korea, Republic of
PETHEMA Foundation
Bristol-Myers Squibb; Celgene; Adknoma Health Research, S.L.

Terminated

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Multiple Myeloma

Spain

Search clinical trials for: BNT153

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations